Samphire Neuroscience has raised $5M in Series A funding to expand its Nettle device targeting menstrual pain, led by Inventure VC and backed by Fortify Ventures.

Samphire Neuroscience has raised $5 million in Series A funding to expand its Nettle brain device for menstrual symptoms. The round was led by Nordic venture capital firm Inventure VC, with participation from US-based Fortify Ventures. The funding will support continued commercial expansion and development of the company’s neurotechnology platform targeting women’s health conditions. Nettle offers a non-hormonal alternative for chronic menstrual issues, showing strong market demand since its recent European launch.